Astrantus’s CRISPR Therapeutics CRSP Stock Holding History

Astrantus’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,000	Closed	-$227K	–	200
2021 Q4	$227K	Buy	+3,000	New	+$262K	0.17%	190

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Astrantus's CRSP Position: Q1 2022 in Review

Astrantus sold out of CRISPR Therapeutics (CRSP) in Q1 2022, closing a stake of 3,000 shares — an estimated $227K sold.

Astrantus first reported a position in CRSP in Q4 2021 and held it in 1 quarter. The position peaked at $227K in Q4 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q1 2022.

Astrantus reported no remaining CRISPR Therapeutics position as of Q1 2022 after selling out during the quarter.
Astrantus sold 3,000 CRISPR Therapeutics shares in Q1 2022, an estimated $227K.
Astrantus first reported a position in CRISPR Therapeutics in Q4 2021 and held it in 1 quarter.
Astrantus's CRISPR Therapeutics position peaked at $227K in Q4 2021.
446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2022.

Based on Astrantus's 13F filing for Q1 2022, filed 11 May 2022.